Monthly Archives: March 2009

March Issue of Pharm Exec Online Now

By George Koroneos | Published: March 13, 2009
The March issue of Pharmaceutical Executive Magazine is online and in the mail as we speak. The new issue features insights into the Pfizer/Wyeth merger, our annual media audit, a look at the new sales force model, and the 2009 Ad Stars. Click here to check it out. The March issues also comes with the [...]
Posted in Pharm Exec Magazine | Tagged , , , , , , | Leave a comment

Roche and Genentech Seal the Deal
for $46.8 Billion

By George Koroneos | Published: March 12, 2009
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it’s been looking for: Genentech’s board of directors, this morning, approved Roche’s latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. Roche plans to keep the Genentech site in [...]
Posted in Biotech | Tagged , , , , , , | 1 Comment

Follow Pharm Exec on Twitter

By George Koroneos | Published: March 11, 2009
Pharm Exec is jumping on the Twitter bandwagon. Starting today, we’re going to be posting regular tweets about the latest pharma news, gossip, and industry updates. Twitter appears to be at the forefront of the microblog revolution and is a much simpler technology to use for live event coverage and executive move updates. I promise [...]
Posted in Strategy | Leave a comment

Merck/Schering-Plough Merger Highlights (Update 1)

By George Koroneos | Published: March 9, 2009
Merck and Schering-Plough’s CEOs are giving a run down of the benefits of the $41.1 billion merger, announced this morning, in a conference call with investors. Here are some of the highlights: • Total price of the sale will be $41.1 billion or $23.6 per Schering share. • This deal is structured as a reverse merger with [...]
Posted in Deals, Strategy | Tagged , , , , , , | 4 Comments

Schering-Plough to Merge with Merck for $41.1 Billion

By George Koroneos | Published: March 9, 2009
Merck’s Richard T. Clark Image via Wikipedia Merck announced, a little over an hour ago, that it had signed an agreement with Schering-Plough’s board of directors to merge the two companies under the Merck name. The stock and cash transaction is worth over $41 billion with Schering shareholders receiving $10.50 per share in cash and 0.5767 of a [...]
Posted in Deals | Tagged , , , , , | Leave a comment